Hisamitsu Pharmaceutical Co Inc represents values of innovation, quality, and commitment to improving healthcare. With a strong corporate philosophy, the company aims to provide effective and safe pharmaceutical products to enhance people's well-being. Its focus on research and development has led to breakthroughs in drug delivery systems, including its flagship product, the PAIN PATCH. By continuously investing in technological advancements and maintaining high standards, Hisamitsu Pharmaceutical Co Inc sets itself apart as a trusted and reputable company in the pharmaceutical industry.

Hisamitsu Pharmaceutical Co Inc is primarily present in Japan, where it is headquartered and has a strong market presence. As a leading pharmaceutical company, Hisamitsu has expanded its operations internationally and is also present in various countries and regions worldwide. Some of the key markets where Hisamitsu Pharmaceutical Co Inc operates include the United States, Europe, China, Asia-Pacific, and other regions. With its diverse range of healthcare products and global reach, Hisamitsu Pharmaceutical Co Inc continues to contribute to the well-being of people across different countries and regions.

Some significant milestones achieved by Hisamitsu Pharmaceutical Co Inc include the development of the world's first topical patch for pain relief, the launch of their flagship product Salonpas, which has become a globally recognized brand, and their continuous research and development efforts in pharmaceutical technology. Additionally, Hisamitsu Pharmaceutical Co Inc has expanded its global presence through strategic partnerships and acquisitions, strengthening its position in the international market. Their commitment to innovation and high-quality healthcare products has garnered them numerous accolades and recognition within the industry.

Hisamitsu Pharmaceutical Co Inc is a renowned Japanese company with a rich history and background in the pharmaceutical industry. Founded in 1847, Hisamitsu has been dedicated to providing innovative healthcare solutions to improve people's lives. With a focus on the development and manufacturing of pharmaceutical products, the company has established itself as a leader in transdermal drug delivery systems. Hisamitsu Pharmaceutical Co Inc has grown into a global entity, operating in various countries and expanding its product portfolio to include a wide range of over-the-counter medicines, medical devices, and prescription drugs. With a commitment to research, quality, and customer satisfaction, Hisamitsu continues to contribute to the advancement of healthcare worldwide.

The main competitors of Hisamitsu Pharmaceutical Co Inc in the market include large pharmaceutical companies such as Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, and Astellas Pharma Inc. Additionally, other competitors may include global pharmaceutical companies like Pfizer Inc. and Novartis AG. These companies compete with Hisamitsu Pharmaceutical Co Inc in various therapeutic areas, including pain management and patches.

Hisamitsu Pharmaceutical Co Inc is primarily active in the pharmaceutical industry.

The business model of Hisamitsu Pharmaceutical Co Inc focuses on the development, manufacturing, and sales of pharmaceutical products. As a leading Japanese pharmaceutical company, Hisamitsu Pharmaceutical specializes in producing transdermal therapeutic patches, such as the popular brand Salonpas. By utilizing innovative drug delivery systems and advanced research, the company aims to provide effective and convenient solutions for pain relief and healthcare. With a strong emphasis on quality and customer satisfaction, Hisamitsu Pharmaceutical continues to expand its product portfolio and global presence, addressing the diverse healthcare needs of individuals worldwide.

Hisamitsu Pharmaceutical Co의 P/E 비율은 13.98입니다.

Hisamitsu Pharmaceutical Co의 P/S 비율은 1.95입니다.

Hisamitsu Pharmaceutical Co에 대한 AlleAktien 품질 점수는 5/10입니다.

Hisamitsu Pharmaceutical Co 매출은 156.01 조. JPY입니다.

Hisamitsu Pharmaceutical Co 이익은 21.76 조. JPY입니다.

Hisamitsu Pharmaceutical Co Inc is a Japanese company specializing in the manufacture and sale of pharmaceutical products. It has a wide range of medicines for the treatment of musculoskeletal, respiratory, cardiovascular, and skin disorders. The business model of Hisamitsu is based on researching and developing new drugs, as well as marketing and distributing these products globally. The company conducts research and development worldwide to continuously expand its product range and meet the needs of consumers. Hisamitsu's medicines are divided into different categories, including pain relief, dermatology, gastroenterology, and respiratory diseases. In the pain relief category, the company offers various products such as pain patches, ointments, and creams used to relieve joint pain, muscle soreness, and other pain symptoms. In the dermatology category, Hisamitsu produces innovative medications for the treatment of skin diseases such as acne, eczema, and dermatitis. In the gastroenterology category, Hisamitsu offers medications for the treatment of gastrointestinal disorders such as heartburn, acid reflux, and digestive disorders. In the respiratory diseases category, the company provides products for the treatment of conditions like asthma, chronic obstructive pulmonary disease (COPD), and seasonal allergic rhinitis. Hisamitsu has a wide distribution network and sells its products in over 60 countries worldwide. It collaborates with various partners, retailers, and health organizations to ensure that its products are available in every region globally. The company also operates an extensive research and development department to further develop its innovative medications. It invests significant resources in the search for new active ingredients that can be used to treat conditions that have not been addressed previously. Hisamitsu's business model also includes collaboration with other companies to develop and jointly market innovative products. Collaborating with other manufacturers allows Hisamitsu to diversify its product range and reach a broader customer base. Overall, Hisamitsu's business model is based on a combination of research and development, distribution partnerships, and a strong presence in the global market. With a wide range of innovative pharmaceutical products and a strong commitment to research and development of new medications, Hisamitsu Pharmaceutical Co Inc has established a leading position in the pharmaceutical industry and will play an important role in improving the health and well-being of people worldwide in the future.

Hisamitsu Pharmaceutical Co은(는) 연간 번의 배당을 통해 42.25 JPY의 배당금을 지급합니다.

Hisamitsu Pharmaceutical Co의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Hisamitsu Pharmaceutical Co의 ISIN은 JP3784600003입니다.

Hisamitsu Pharmaceutical Co의 WKN은 864341입니다.

Hisamitsu Pharmaceutical Co의 티커는 4530.T입니다.

지난 12개월 동안 Hisamitsu Pharmaceutical Co은(는) 47 JPY 의 배당금을 지급했습니다. 이는 약 1.14 %의 배당 수익률에 해당합니다. 향후 12개월 동안 Hisamitsu Pharmaceutical Co은(는) 47.91 JPY의 배당금을 지급할 것으로 예상됩니다.

Hisamitsu Pharmaceutical Co의 현재 배당 수익률은 1.14 %입니다.

Hisamitsu Pharmaceutical Co은 분기별로 배당금을 지급합니다. 이는 , , , 월에 배당됩니다.

Hisamitsu Pharmaceutical Co은(는) 지난 23년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 47.91 JPY의 배당금이 예상됩니다. 이는 배당수익률 1.16 %에 해당합니다.

Hisamitsu Pharmaceutical Co은 '건강' 섹터에 속합니다.

Hisamitsu Pharmaceutical Co의 마지막 배당금을 45 JPY만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2024년에 Hisamitsu Pharmaceutical Co는 44.5 JPY를 배당금으로 지급했습니다.

Hisamitsu Pharmaceutical Co의 배당금은 JPY에 지급됩니다.